Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research
September 14, 2023 09:51 ET
|
Emergen Research
Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
August 01, 2023 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...
Aptose Presents Highlights from Clinical Update
June 10, 2023 12:00 ET
|
Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
May 11, 2023 16:05 ET
|
Vor Biopharma
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...
Woman Finally Meets Stem Cell Donor Who Saved Her Life
May 10, 2023 11:07 ET
|
Gift of Life Marrow Registry
BOCA RATON, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Two strangers, who are now deeply connected through a lifesaving blood stem cell transplant, met for the first time at Gift of Life Marrow...
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market to Grow by $1.65 Billion During 2023-2027
March 15, 2023 08:13 ET
|
Research and Markets
Dublin, March 15, 2023 (GLOBE NEWSWIRE) -- The "Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.The BCL-2 (B-cell Lymphoma...
Cancer Biomarkers Market to Accrue $34.85 Billion, by 2028 - Global Analysis by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Leukemia, Bladder Cancer)
March 09, 2023 08:35 ET
|
The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, "Cancer Biomarkers Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
January 23, 2023 07:01 ET
|
Consilium Strategic Communications
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy of SMART101 in accelerating immune reconstitution to...
Global Hemato Oncology Testing Market Report 2022 to 2027: Drug Diagnostics Co-Development Presents Opportunities
December 12, 2022 08:14 ET
|
Research and Markets
Dublin, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022 09:00 ET
|
Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...